The course of vitrectomy for diabetic macular edema (DME) in 10 intraocular lens (IOL) eyes

Poster Details

First Author: E.Tomoyori JAPAN

Co Author(s):    A. Nakamura   K. Endo   Y. Wada   T. Usui   K. Fujisawa   H. Takahashi              

Abstract Details


Anti-vascular endothelial growth factor (anti-VEGF) intravitreal injection has become the first-line for the treatment of diabetic macular edema (DME). On the other hand, the effect of vitrectomy is also recognized. In this study, we examined visual acuity (VA) and central retinal thickness (CRT) for 10 eyes who underwent vitrectomy for DME in IOL (intraocular lens) eyes that can exclude the effect of cataract. We limited the subjects of this study to IOL eyes. This is to eliminate the effects of cataract and cataract surgery.


The subjects of this study are 10 IOL eyes that have been followed for more than 6 months after surgery. In 5 eyes, anti-VEGF intravitreal injection was used at the same time as vitrectomy. The subjects had undergone surgery from April 2014 until March 2015.


We retrospectively compared VA and CRT at the preoperation and the end of observation period. VA was evaluated by converting desimal VA to LogMAR VA.


The final VA improved to 0.36 compared with 0.57 of the baseline. Only one eye got worse from 0.22 to 0.40. The final CRT improved to 245.2µm compared with 423.6µm of the baseline. There was no case deteriorated by more than 10%. During the observation period, there was no case that anti-VEGF intravitreal injection was given as postoperative treatment.


Vitrectomy for DME is effective and can prevent repeated administration of anti-VEGF intravitreal injection.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy